Here are five things to know:
1. NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the five-year, $2.2 million grant.
2. Dr. Lieberman will use the grant for gene therapy research on how to enhance repair of bone injuries.
3. Specifically, his research will focus on fractures with excessive bone loss, non-healing fractures, failed spinal fusions and total joint replacement revisions.
4. For his research, Dr. Lieberman will genetically manipulate human bone marrow cells to overproduce bone morphogenetic protein.
5. Ultimately, his research will test the efficacy and safety of the gene therapy and “establish a cellular dose of the genetically manipulated cells that can be scaled up for potential use in humans.”
“My goal with this grant is to determine whether genetically modifying human bone marrow cells to overproduce BMP will help heal large bone defects in an animal model and, ultimately, provide a better alternative for repairs in humans,” said Dr. Lieberman.
More articles on spine:
Neurosurgeon wins $88.7k+ in retaliation case against NY hospital over concurrent surgeries: 5 things to know
4 key notes on the best method for measuring cervical spine sagittal alignment
Dr. Joseph Cheng to lead University of Cincinnati neurosurgery department — 7 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
